[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100349178":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":58,"collaborators":18,"id":60,"slug":18,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":18,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Sclnow Biotechnology Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6\\*10\\^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 \\* 10 \\^ 7 (30 ml)",[13],"Biological: Peripheral iv",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Control Group: Using basic contrast .",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BIOLOGICAL","Peripheral iv","6\\*10\\^7 cells",[9],[26],{"name":27,"affiliation":28,"role":29},"Xuegong Fan, doctor","Xiangya Hospital of Central South University","STUDY_DIRECTOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Lei Guo, doctor","CONTACT","861064368977","georgeguo@sclnow.com",{"name":27,"role":33,"phone":37,"phoneExt":18,"email":38},"86731-84327392","xgfan@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Xiangya Hospital Central South University","RECRUITING","Changsha","Hunan","410008","China",{"type":48,"coordinates":49},"Point",[50,51],112.97087,28.19874,{"lat":51,"lon":50},[54,57],{"name":55,"role":33,"phone":56,"phoneExt":18,"email":18},"ShaLing Li, doctor","8613975186154",{"name":27,"role":33,"phone":37,"phoneExt":18,"email":38},{"type":59,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100349178",false,"NCT03826433","hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosis","Inclusion Criteria:\n\n* Age 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg\u002Fm2, including boundary value;\n* The diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score≤21 points.\n* Have not received stem cell therapy in the recent 6 months;\n* Subjects will be able to sign the informed consent in accordance with the study procedures and instructions.\n\nExclusion Criteria:\n\n* Insufficiency of vital organs, such as heart, kidney and lung;\n* End-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc.\n* Concomitant peritonitis, pneumonia, or other types of infection not under control;\n* Have a history of severe allergic reaction or allergy to two or more kinds of food or medicine;\n* Positive serum HIV antibody and syphilis antibody;\n* Alpha fetoprotein\\>400ng\u002FmL with primary liver cancer or without imaging evidence;\n* Chronic liver disease and cirrhosis are caused by non-chronic hepatitis B virus infection, or other factors except chronic hepatitis B virus infection ;\n* Patients with severe mental illness and cognitive impairment;","ALL","18 Years","60 Years",{"count":70,"type":71},20,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.\n2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat.\n3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.",[77],"Hepatitis B",[79],"Hepatitis B Cirrhosis, mesenchymal stem cell","2026-04-22",{"date":82,"type":83},"2026-04-23","ACTUAL",{"date":85,"type":83},"2018-10-01",{"date":87,"type":71},"2027-12-31",{"name":5,"class":6},1]